CRDF · Cardiff Oncology Inc
United States · RS rating 19 · As of 2026-11-03
| Price | 0.86 USD |
|---|---|
| 1-day change | +2.8% |
| RS rating (overall / 1M / 3M / 12M) | 19 / 17 / 46 / 15 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 17 / 7 / 21 |
| Industry group (rank) | Medical-Research Eqp/Svc (46) |
| EPS growth Q/Q | +22.2% |
| Sales growth Q/Q | +102.5% |
| Distance from 52-week high | +73.1% |
| Market cap (USD) | $114.2M |